DGAP-Adhoc: FDA approves once-monthly Abilify Maintena (aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia
H. Lundbeck A/S
01.03.2013 00:01
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
-- Approval provides patients with schizophrenia the ability to access the
efficacy and safety profile of oral aripiprazole in a once-monthly
formulation
-- Relapse prevention is an important consideration in the tr
Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news